Lilly's profit forecast bring investors some relief amid Zepbound miss
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns about signs of weakness in sales of its popular diabetes and weight-loss treatments.
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound.
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Lilly Profit View ‘Enough to Pacify Investors’ After Sales Miss
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on sales in recent quarters.
Eli Lilly expects to beat profit forecasts on obesity drug demand
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.
Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after another quarter of sales miss for its popular diabetes and weight-loss treatments.
Lilly issues 2025 profit view as it steers for revenue boost
Eli Lilly & Co. said it expects to generate adjusted 2025 profit of $22.50 a share to $24 a share in 2025. That compares to the FactSet consensus estimate of $22.76 a share for 2025. Lilly’s 2025 revenue target of $58 billion to $61 billion compares to the analyst estimate of $58.
Eli Lilly Stock Rises After Earnings Beat Forecasts
Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter.
BioSpace9h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
FiercePharma1d
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Why Eli Lilly Stock Popped on Thursday
Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...